Publications by authors named "Kelly Frazier"

Claim this Profile
C
Correction to: Metabolic relevance for N-hydroxy L-arginine reduction in estrogen-negative breast cancer cells.
Srinidi Mohan, Seema Patel, Ian Greenstein, Cathy Ng, Kelly Frazier

Amino Acids· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic relevance for N-hydroxy L-arginine reduction in estrogen-negative breast cancer cells.
Srinidi Mohan, Seema Patel, Ian Greenstein, Cathy Ng, Kelly Frazier

Amino Acids· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing N -hydroxy-L-arginine applicability as a novel ethnic specific estrogen-negative breast cancer marker.
Srinidi Mohan, Ian Greenstein, Cathy Ng, Kelly Frazier, Giang Nguyen

Amino Acids· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.
Matthew T Burger, Sabina Pecchi, Allan Wagman, Zhi-Jie Ni, Mark Knapp, Kelly Frazier

ACS Med Chem Lett· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors.
Matthew T Burger, Mark Knapp, Allan Wagman, Zhi-Jie Ni, Thomas Hendrickson, Kelly Frazier

ACS Med Chem Lett· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors.
Paul A Renhowe, Sabina Pecchi, Cynthia M Shafer, Timothy D Machajewski, Elisa M Jazan, Kelly Frazier

J Med Chem· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and structure-activity relationship of heterocyclic analogs of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones as inhibitors of receptor tyrosine kinases.
Kelly Frazier, Elisa Jazan, Christopher M McBride, Sabina Pecchi, Paul A Renhowe

Bioorg Med Chem Lett· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis